Guest article by Dr Srinivas Chilukuri
About 18.1 million people worldwide were diagnosed with cancer in 2018. Around 1-2% of this, numbering approximately 300,000 are children younger than 15 years. Improved survival outcomes among the paediatric (childhood) cancer patients have been one of the major success stories of modern medicine in the last 3 decades. Dramatic improvements in the survival rates of leukemias, lymphomas and sarcomas are notable achievements. Most of these improvements can be attributed to multimodality, multidisciplinary treatments apart from improvements in supportive care such as availability of blood products, antibiotics, antiemetics and cytokines. The exponential successes of paediatric cancer management engender the new and complex challenge of caring for the growing number of survivors. The prolonged treatment brings upon us the tremendous burden of late side effects related to physical, biological, psychological and social well-being including increased incidence of second cancers. These effects are more profound when the child is treated at a younger age.
X-Ray or Photon Radiation – A Double Edged Sword: Radiation alone or in combination with chemotherapy and surgery is an important and life saving treatment for most of the paediatric cancers. Conventionally, radiation is delivered through high energy X-rays (or photons) and approximately 99% of patients receiving radiation do so with high energy X-rays. Radiation, despite improving outcomes, is a significant contributor to the burden of later effects. The proliferating cells in developing tissues in paediatric patients are extremely susceptible to radiation-induced damage. Low dose radiation bath to the body significantly increases the risk of second cancers. Very little radiation doses to the immature brain in children younger than 10 years may lead to irreversible neuro-cognitive and behavioural effects. Several studies on cardiovascular effects have shown the same regarding cardiac events correlated to dose received either by the heart, the coronaries or the left ventricle. Physically, children suffer from increased fatigue, memory loss, and audiovisual deficits. Their psychological health is affected adversely by fear of tumour relapse, future uncertainty, and lower self-esteem due to functional impairments. Interpersonal relationships including familial and social bonding are consequently worse. For paediatric survivors, decline in concentration, easy fatigability, and physical and mental impairments contribute to overall worse school performance.
Emphasis on survivorship: The key emphasis in childhood cancers has now shifted to how best a child can be treated successfully without adversely altering the opportunities, aspirations and expectations of both the children as well as their families. The major focus is to recognise the effects due to treatment as well as mechanisms to mitigate or minimize these effects. In the past decade, there has been a major emphasis on ‘de-intensification’ or reduction in the amount of treatment with reduction of chemotherapy and radiation doses as well as treatment volumes in the children’s oncology group trials. These modifications were being carried out cautiously without affecting survival outcomes and yet they have been successful only to a limited extent.
A new ray of hope- Proton therapy: One of the new and a major advancement has been proton therapy for this group of patients. In theory, proton therapy, has the ability to stop in the tumor which is ideally suited for all paediatric patients requiring radiation therapy. Protons have completely different physical properties compared to X-rays. High energy X-rays deposit their peak energy just below the skin surface and deposit moderate doses to the tumour (compared to the peak) and continue to deposit the dose along the entire path until the beam exits the patient. By contrast, proton beams enter and pass through the tissue with minimal dose until they reach the end of their paths, where the peak of energy deposition happens followed by almost no ‘exit dose’ which means no dose beyond the tumour is given. By eliminating exit dose, protons confine the high dose region to the target volume and minimize dose to surrounding structures. This pattern of their energy deposition is called a Bragg peak (See Figure 1 & 2).
Numerous comparative studies have demonstrated that proton therapy is advantageous over conventional X-ray radiation therapy, intensity modulated radiation therapy (IMRT), or both, including in paediatric cancers. These studies that have concluded that proton therapy achieves better dose coverage to the tumours, helps to spare normal tissues, and lowers the overall dose received by the entire body. At best centres across the world, proton therapy is the standard of care to treat children with cancers that require radiation therapy as a part of their multi-modality treatment.
Major Benefits of Proton Therapy: Proton therapy is being used in paediatric patients to reduce the late-effects on growth and development, neuro-cognition, neuroendocrine function, cardiovascular effects, bone marrow effects, effects on viscera such as kidneys, lungs, bowel and second malignancies. A study from Harvard University published in 2015 (Pulsifer M, et al. IJROBP 2015) showed no decline in mean Wechsler Full Scale IQ, verbal comprehension, perceptual reasoning, organization skills or working memory in 67 children who received proton therapy for their brain tumours. Study from the same group also showed significant reduction in the incidence of second cancers in children who received proton therapy compared to those children who received high energy X-rays.
Figures 1 & 2 show how Proton beam radiation therapy helps avoid damage to healthy surrounding tissues by depositing majority of radiation energy in the tumour.
Authored by Dr Srinivas Chilukuri, a Senior Radiation Oncologist & Proton Therapy Expert and member of Onco.com expert oncologists panel. He specializes in high-precision radiation therapy, brain and spine tumors, head and neck cancers, lung cancer and gastrointestinal cancer.